Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout ...
TMCnet

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the ...

Neuphoria Therapeutics, Inc.: Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fisca ...
Becker's Hospital Review

Inside Temple Health’s predictive insulin rollout: What worked and what’s next

After launching a multi-campus phased rollout of the predictive insulin dosing software, Philadelphia-based Temple Health’s University Hospital has reduced hypoglycemia rates two- to threefold.   The ...
NFL

Kiran Amegadjie Draft and Combine Prospect Profile | NFL.com

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience. The ...